小分散聚合物,斑块,纠和动态平衡:解开阿尔茨海默病的纠
Emre Fertan1,2, Georg Meisl1,2, David Klenerman1,2
1Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
概括
小,可溶性聚合物的β-粉样和可能驱动阿尔茨海默病的进展. 大脑积极形成较大的斑块和结,作为对这些有毒的较小物种的保护性反应.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 的特点是β-粉样质斑块和tau结.
- 这些聚合物在AD病理生理学中的确切作用尚不清楚.
- 比较小的β-粉样和的可溶性聚合物可能比较有毒,大,不溶性斑块和.
研究的目的:
- 假设小和大β-粉样和聚合物的形成是一个非线性过程.
- 探索调节AD中可溶性与不可溶性聚合物的形成的差异机制.
主要方法:
- 综合了作者组的最新发现和其他关键研究.
- 整合现有关于阿尔茨海默病聚合物形成和清除的知识.
主要成果:
- β-粉样和的小型扩散聚合物形成是一种被动的,热力学调节的过程.
- 大型不溶性聚合物形成 (斑块和) 是微质和神经元调节的活跃过程.
- 斑块和的活跃形成可以作为对较小,更有毒的聚合物的保护机制.
结论:
- 在生产和清除β-粉样和tau聚合物的不平衡可能驱动AD病理.
- 斑块和结形成可能代表大脑积极,尽管可能不足,试图恢复平衡.
- 了解可溶性和不可溶性聚合物的不同形成途径对于开发有效的阿尔茨海默病治疗方法至关重要.
相关概念视频
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Alzheimer's Disease: Overview
675
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Dementia
173
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
173


